Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab in Schnitzler syndrome (phase II, open-label, proof-of-concept)
2013-002562-39Phase 2Completed
- Sponsor
- Servier
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gevokizumab in Schnitzler syndrome, sponsored by Servier. Primary endpoints: Exploratory efficacy endpoints and Safety endpoints. Started Jul 2013; status: completed.
02
Drugs
gevokizumab
03
Conditions
Schnitzler syndrome
Beyond the preview
Go deeper on 2013-002562-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002562-39.